PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
10193766-11	1999	In addition, the relaxations induced by PGD2 were significantly inhibited by treatment with a DP-receptor antagonist BWA868C (0.1 microM; n=3).	BW A868C	117-124	prostaglandin D2 synthase	Homo sapiens	40-44
22503964-4	2012	C5a-induced anxiolytic-like activity was inhibited by indomethacin, a cyclooxygenase inhibitor, or BWA868C, an antagonist of DP(1) receptor for PGD(2), respectively.	BW A868C	99-106	hemolytic complement	Mus musculus	0-3
22564055-7	2012	The anxiolytic-like activity of ovolin was inhibited by indomethacin, a cyclooxygenase (COX) inhibitor, or BWA868C, an antagonist of the DP1 receptor for prostaglandin (PG) D2 .	BW A868C	107-114	transcription factor Dp 1	Mus musculus	137-140
19800413-4	2009	The orexigenic activity of C5a was blocked by co-administration of a DP(1) receptor antagonist, BWA868C.	BW A868C	96-103	hemolytic complement	Mus musculus	27-30
15388786-10	2005	The DP(1) receptor antagonist BWA868C [3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)-4-imidazolidine-heptanoic acid] enhanced PGD(2)-induced CD203c expression, suggesting that interaction of PGD(2) with DP(1) receptors can limit activation of basophils by this prostaglandin.	BW A868C	30-37	ectonucleotide pyrophosphatase/phosphodiesterase 3	Homo sapiens	161-167
8019753-13	1994	PGD2 caused a facilitation of evoked tritium overflow in the saphenous vein; this facilitation is probably mediated by presynaptic DP-receptors, since it was abolished by the selective DP-receptor antagonist, BW A868C (3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)hydantoin).5.	BW A868C	219-292	prostaglandin D2 synthase	Homo sapiens	0-4
8384001-7	1993	These cyclic AMP and [Ca2+]i responses induced by PGD2 were completely blocked by the PGD2 receptor antagonist BWA868C.	BW A868C	111-118	prostaglandin D2 receptor	Bos taurus	86-99